CN112375797B - 一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法 - Google Patents
一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法 Download PDFInfo
- Publication number
- CN112375797B CN112375797B CN202011150316.0A CN202011150316A CN112375797B CN 112375797 B CN112375797 B CN 112375797B CN 202011150316 A CN202011150316 A CN 202011150316A CN 112375797 B CN112375797 B CN 112375797B
- Authority
- CN
- China
- Prior art keywords
- fermentation
- ademetionine
- adenosylmethionine
- culture medium
- hpo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- VERAMNDAEAQRGS-UHFFFAOYSA-N butane-1,4-disulfonic acid Chemical compound OS(=O)(=O)CCCCS(O)(=O)=O VERAMNDAEAQRGS-UHFFFAOYSA-N 0.000 title abstract description 24
- 229960001570 ademetionine Drugs 0.000 claims abstract description 47
- 238000000855 fermentation Methods 0.000 claims abstract description 47
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 46
- 230000004151 fermentation Effects 0.000 claims abstract description 46
- 239000001530 fumaric acid Substances 0.000 claims abstract description 23
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 23
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims abstract description 21
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims abstract description 21
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 21
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 18
- 229960004452 methionine Drugs 0.000 claims abstract description 18
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930195722 L-methionine Natural products 0.000 claims abstract description 10
- FUDAIDRKVVTJFF-UHFFFAOYSA-N butane-1,1-disulfonic acid Chemical compound CCCC(S(O)(=O)=O)S(O)(=O)=O FUDAIDRKVVTJFF-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001963 growth medium Substances 0.000 claims description 21
- 239000002609 medium Substances 0.000 claims description 19
- 238000011218 seed culture Methods 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 12
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 12
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000001888 Peptone Substances 0.000 claims description 6
- 108010080698 Peptones Proteins 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 235000019319 peptone Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 5
- 229960005305 adenosine Drugs 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- DMNNAGLOODQTOQ-HXTWIPGBSA-N [C@@H]1([C@H](O)[C@H](O)[C@@H](CN[C@@H](CCSC)C(=O)O)O1)N1C=NC=2C(N)=NC=NC12.C(CCCS(=O)(=O)O)S(=O)(=O)O Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CN[C@@H](CCSC)C(=O)O)O1)N1C=NC=2C(N)=NC=NC12.C(CCCS(=O)(=O)O)S(=O)(=O)O DMNNAGLOODQTOQ-HXTWIPGBSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- AUHYYKRJXKWYST-WCCKRBBISA-N (2S)-2-amino-4-methylsulfanylbutanoic acid butane-1,4-disulfonic acid Chemical compound CSCC[C@H](N)C(O)=O.OS(=O)(=O)CCCCS(O)(=O)=O AUHYYKRJXKWYST-WCCKRBBISA-N 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 abstract description 8
- 108090000364 Ligases Proteins 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 3
- 230000007872 intrahepatic cholestasis Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical group [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 108700022128 Hypermethioninemia Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000022837 disorder of methionine catabolism Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000008245 hypermethioninemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002613 pineal body hormone Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- -1 sulfhydryl compound Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供了一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法,属于制药技术领域。本发明在实施过程中在发酵培养基中加入含量比为2‑4:1‑2:1‑2的脯氨酸、延胡索酸和Na2HPO4·12H2O能够提高腺苷蛋氨酸合成酶的表达水平,提高生物体内腺苷蛋氨酸合成酶的催化活力,能够保证发酵体系中外加较低含量的三磷酸腺苷即可提高L‑蛋氨酸的转化率;得到的腺苷蛋氨酸与丁二磺酸反应效率高,使制备得到的丁二磺酸腺苷蛋氨酸产品纯度明显提高。
Description
技术领域
本发明属于制药技术领域,具体涉及一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法。
背景技术
丁二磺酸腺苷蛋氨酸是人体组织和体液中普遍存在的一种生理活性分子。它做为甲基供体(转甲基作用)和生理性巯基化合物(如半胱氨酸、牛磺酸、谷胱甘肽和辅酶A等)的前体(转硫基作用)参与体内重要的生化反应。在临床上用于治疗抑郁症、关节炎、肝功能紊乱等疾患,也适用于肝硬化前和肝硬化所致肝内胆汁淤积,适用于妊娠期肝内胆汁淤积。其药理作用为:腺苷蛋氨酸是存在于人体所有组织和体液中的一种生理活性分子。它作为甲基供体(转甲基作用)和生理性硫基化合物(如半胱氨酸,牛磺酸,谷胱甘肽和辅酶A等)的前体(转硫基作用)参与体内重要的生化反应。在肝内,通过使质膜磷脂甲基化而调节肝脏细胞膜的流动性,而且通过转硫基反应可以促进解毒过程中硫化产物的合成。只要肝内腺苷蛋氨酸的生物利用度在正常范围内,这些反应就有助于防止肝内胆汁淤积。现已发现,肝硬化时肝内腺苷蛋氨酸的合成明显下降,这是因为腺苷蛋氨酸合成酶(催化必需氨基酸蛋氨酸向腺苷蛋氨酸转化)的活性显著下降(-50%)所致。这种代谢障碍使蛋氨酸向腺苷蛋氨酸转化减少,因而削弱了防止胆汁淤积的正常生理过程。结果使肝硬化病人饮食中的蛋氨酸血浆清除率降低,并造成其代谢产物,特别是半胱氨酸,谷胱甘肽和牛磺酸利用度的下降。而且这种代谢障碍还造成高蛋氨酸血症,使发生肝性脑病的危险性增加。有研究证明体内蛋氨酸累积可导致其降解产物(如硫醇,甲硫醇)在血中的浓度升高,而这些降解产物在肝性脑病的发病机理中起重要作用。由于腺苷蛋氨酸可以克服腺苷蛋氨酸合成酶不足的障碍,故应用腺苷蛋氨酸可以使巯基化合物合成增加,但不增加血循环中蛋氨酸的浓度。给肝硬化病人补充腺苷蛋氨酸可以使一种在肝病时生物利用度降低的必需化合物恢复其内源性水平。经研究发现腺苷蛋氨酸的抗胆汁淤积作用与其下列作用有关:⑴促进腺苷蛋氨酸-依赖性质膜磷脂的合成(降低胆固醇/磷脂的比例)而恢复细胞质膜的流动性;⑵克服转硫基反应障碍,促进了内源性解毒过程中硫基的合成。
丁二磺酸腺苷蛋氨酸是一种良好的肝脏营养剂,可防止酒精、药物和细胞素对肝脏的损伤;防止胆汁积淤;预防慢性活动性肝炎以及其他因素而造成的肝损伤。预防由于缺氧而造成的神经细胞坏死即缺氧症;促进神经细胞和神经纤维的组织再生。预防心脏疾病、癌症以及其他疾病的发生。治疗关节炎等疾病。抗抑郁症,效果好于常规的临床药物,而且副作用少;松果体素合成所必需的前提物质,具有消炎、减轻疼痛及组织修复功能,对关节病疗效显著,具有明显促进软骨生成和减轻关节疼痛、僵硬和肿胀的功效。
中国专利申请201210269772.6中公开了一种丁二磺酸腺苷蛋氨酸的制备方法,对菌株酿酒酵母依次进行种子培养、发酵和精制后得到丁二磺酸腺苷蛋氨酸成品,具有发育周期短,分离效果好,纯品纯度高等优点。但是根据其公开的内容可知其并没有对丁二磺酸腺苷蛋氨酸成品的收率进行研究,若实际生产中产品的纯度很高,但是的收率低,依然没有应用前景。
因此,需要提供一种收率高,纯度好的丁二磺酸腺苷蛋氨酸制备方法。
发明内容
基于现有技术中的不足,本发明提供了一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法,本发明中提供的方法腺苷蛋氨酸的产品收率高,进而使制备的丁二磺酸腺苷蛋氨酸纯度和收率均能达到理想效果。
本发明通过以下技术方案解决上述技术问题:
一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法,包括以下步骤:
(1)将腺苷蛋氨酸产生菌接入活化培养基中,培养温度为24-32℃,培养3-5天,得到活化菌株;
(2)将步骤(1)中得到的活化菌株接种于一级种子培养基中,培养温度为24-32℃,培养12-25小时,得到一级种子;再将一级种子接种于下一级种子培养基中,培养温度为24-32℃,培养12-25小时,得到二级种子;
(3)将步骤(2)中得到的二级种子接入发酵培养基中,培养温度为24-32℃,发酵过程中pH为4.6-5.2,发酵过程中向发酵液中添加三磷酸腺苷和L-蛋氨酸,发酵40-50小时,得到腺苷蛋氨酸发酵液;
(4)将步骤(3)中得到的腺苷蛋氨酸发酵液进行破壁后过滤,纯化,浓缩,得到腺苷蛋氨酸浓缩液;
(5)向步骤(4)得到的腺苷蛋氨酸浓缩液中加入丁二磺酸然后进行冷冻干燥,即得到丁二磺酸腺苷蛋氨酸产品。
上述步骤(1)中所述的活化培养基配方为葡萄糖2-5%、蛋白胨0.2-0.8%、酵母粉0.2-0.8%、琼脂1.2-2.5%;
上述步骤(2)中所述的一级种子培养基和二级种子培养基配方为葡萄糖2-5%、维生素B2 0.2-0.5%、蛋白胨0.2-0.8%、酵母粉0.2-0.8%;
上述步骤(3)中所述的发酵培养基配方为葡萄糖5-8%、蛋白胨1-2%、酵母粉0.5-1.5%、K2HPO4 0.2-0.4%、KCl2 0.02-0.04%,pH为4.6-5.2,优选为4.7-5.1,再优选为4.8-5.0,进一步优选为4.9。
在一些优选实施方案中,上述步骤(3)中所述的发酵培养基配方中还含有脯氨酸0.4-0.8%、延胡索酸0.1-0.2%和Na2HPO4·12H2O 0.1-0.2%。
所述的脯氨酸、延胡索酸和Na2HPO4·12H2O的添加量之比为2-4:1-2:1-2;优选为4:2:1。
上述步骤(3)中所述的添加三磷酸腺苷和L-蛋氨酸为发酵15-20小时以后添加。
本发明在实施过程中意外地发现,在发酵培养基中加入含量比为2-4:1-2:1-2的脯氨酸、延胡索酸和Na2HPO4·12H2O能够明显提高腺苷蛋氨酸的产品收率。
上述步骤(3)中所述的延胡索酸的浓度为5-8mmol/L,优选为6-7mmol/L。
上述步骤(3)中所述的三磷酸腺苷的加入量为发酵培养基的0.4-0.8%,优选为0.5-0.7%,再优选为0.5-0.6%;进一步优选为0.6%;所述的L-蛋氨酸的加入量为发酵培养基的0.8-1.2%,优选为0.9-1.1%,再优选为1.0%。
上述步骤(4)中所述的过滤,纯化,浓缩步骤为本领域常规操作步骤。
上述步骤(5)中所述的腺苷蛋氨酸和丁二磺酸的质量比为1:0.8-1.0。
上述步骤(3)中的接种量为20-30%,优选为25%。
与现有技术相比,本发明的有益效果在于:
(1)本发明在实施过程中发现在发酵培养基中加入含量比为2-4:1-2:1-2的脯氨酸、延胡索酸和Na2HPO4·12H2O能够提高腺苷蛋氨酸合成酶的表达水平,提高生物体内腺苷蛋氨酸合成酶的催化活力,进而提高腺苷蛋氨酸的产品收率;
(2)本发明在培养基中加入脯氨酸、延胡索酸和Na2HPO4·12H2O的混合物能够降低发酵体系中外加三磷酸腺苷的含量(加入量为0.4-0.8%),保证加入较低含量的三磷酸腺苷即可提高L-蛋氨酸的转化率,由于三磷酸腺苷价格比较昂贵,因此本发明在降低成本的基础上提高了腺苷蛋氨酸的产品收率;
(3)本发明制备得到的腺苷蛋氨酸产率高,纯度高,与丁二磺酸反应效率高,使制备得到的丁二磺酸腺苷蛋氨酸产品纯度明显提高。
具体实施方式
本发明所使用的腺苷蛋氨酸产生菌为酒酿酵母BNCC186832,本发明中的%表示的是质量体积百分比(g/L),例如三磷酸腺苷的加入量为发酵培养基的0.4%,表示1L发酵液中加入三磷酸腺苷的质量为0.004g。
实施例1-3一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法,包括以下步骤:
(1)将腺苷蛋氨酸产生菌接入活化培养基中,培养温度为24℃,培养5天,得到活化菌株;
(2)将步骤(1)中得到的活化菌株接种于一级种子培养基中,培养温度为24℃,培养12小时,得到一级种子;再将一级种子接种于下一级种子培养基中,培养温度为24℃,培养12小时,得到二级种子;
(3)将步骤(2)中得到的二级种子接入发酵培养基(发酵液体积50L)中,接种量为25%,培养温度为24℃,发酵15h后向发酵液中添加三磷酸腺苷和L-蛋氨酸,共发酵40小时,得到腺苷蛋氨酸发酵液;
(4)将步骤(3)中得到的腺苷蛋氨酸发酵液进行破壁后过滤,纯化,浓缩,得到腺苷蛋氨酸浓缩液;
(5)向步骤(4)得到的腺苷蛋氨酸浓缩液中加入丁二磺酸,腺苷蛋氨酸和丁二磺酸的质量比为1:0.8,然后进行冷冻干燥,即得到丁二磺酸腺苷蛋氨酸产品。
上述步骤(3)中三磷酸腺苷和L-蛋氨酸的加入量分别为:
使用高效液相色谱法检测腺苷蛋氨酸和丁二磺酸腺苷蛋氨酸的产量,具体检测数据见下表1。
此处检测的腺苷蛋氨酸的产率为步骤(3)中得到的发酵液中腺苷蛋氨酸的产率。
检测腺苷蛋氨酸的条件:C18柱,洗脱液为体积比15:85的甲醇和乙酸铵水溶液,流动相流速为1.0mL/min,检测波长254nm,进样量为20μL;
检测丁二磺酸腺苷蛋氨酸的条件:C18柱,洗脱液为甲酸铵水溶液,流动相流速为1.0mL/min,检测波长260nm,进样量为20μL;
表1
根据上表1的检测数据可以看出三磷酸腺苷的加入量会对腺苷蛋氨酸的产量产生影响,三磷酸腺苷的加入量越高,腺苷蛋氨酸的产量呈上升趋势。
实施例4-6一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法,包括以下步骤:
(1)将腺苷蛋氨酸产生菌接入活化培养基中,培养温度为32℃,培养3天,得到活化菌株;
(2)将步骤(1)中得到的活化菌株接种于一级种子培养基中,培养温度为32℃,培养25小时,得到一级种子;再将一级种子接种于下一级种子培养基中,培养温度为32℃,培养25小时,得到二级种子;
(3)将步骤(2)中得到的二级种子接入发酵培养基中(发酵液体积50L),接种量为25%,培养温度为32℃,发酵20h后向发酵液中添加三磷酸腺苷和L-蛋氨酸,共发酵40小时,得到腺苷蛋氨酸发酵液;
(4)将步骤(3)中得到的腺苷蛋氨酸发酵液进行破壁后过滤,纯化,浓缩,得到腺苷蛋氨酸浓缩液;
(6)向步骤(4)得到的腺苷蛋氨酸浓缩液中加入丁二磺酸,腺苷蛋氨酸和丁二磺酸的质量比为1:1.0,然后进行冷冻干燥,即得到丁二磺酸腺苷蛋氨酸产品。
上述步骤(3)中三磷酸腺苷和L-蛋氨酸的加入量分别为:
使用高效液相色谱法检测腺苷蛋氨酸和丁二磺酸腺苷蛋氨酸的产量,具体检测数据见下表2。
检测腺苷蛋氨酸的条件:C18柱,洗脱液为体积比15:85的甲醇和乙酸铵水溶液,流动相流速为1.0mL/min,检测波长254nm,进样量为20μL;
检测丁二磺酸腺苷蛋氨酸的条件:C18柱,洗脱液为甲酸铵水溶液,流动相流速为1.0mL/min,检测波长260nm,进样量为20μL;
表2
根据上表2的检测数量可以三磷酸腺苷的加入量会对腺苷蛋氨酸的产量产生影响,三磷酸腺苷的加入量越高,腺苷蛋氨酸的产量呈上升趋势,此结论与实施例1-3的结论相同,但是根据表2可知在发酵培养基中加入脯氨酸、延胡索酸和Na2HPO4·12H2O的混合物可以在降低三磷酸腺苷的加入量的基础上提高腺苷蛋氨酸的产量,即根据实施例4可知,当三磷酸腺苷的加入量为0.4%时,腺苷蛋氨酸的产量即可达到3.6g/L,明显高于实施例1,综上脯氨酸、延胡索酸和Na2HPO4·12H2O的加入能够提高腺苷蛋氨酸合成酶的表达水平,提高生物体内腺苷蛋氨酸合成酶的催化活力,进而提高腺苷蛋氨酸的产品收率。
对比例1
与实施例6的区别在于:脯氨酸、延胡索酸和Na2HPO4·12H2O的添加量之比为0.5:1:1,即脯氨酸0.14%、延胡索酸0.28%和Na2HPO4·12H2O 0.28%,其他操作与步骤与实施例6相同。
对比例2
与实施例6的区别在于:脯氨酸、延胡索酸和Na2HPO4·12H2O的添加量之比为1:0.5:2,即脯氨酸0.2%、延胡索酸0.1%和Na2HPO4·12H2O 0.4%,其他操作与步骤与实施例6相同。
对比例3
与实施例6的区别在于:不添加脯氨酸,即延胡索酸0.47%和Na2HPO4·12H2O0.23%,其他操作与步骤与实施例6相同。
对比例4
与实施例6的区别在于:不添加延胡索酸,即脯氨酸0.56%和Na2HPO4·12H2O0.14%,其他操作与步骤与实施例6相同。
表3
根据上表1-3的数据可知,当发酵培养基使用常规培养基时,即实施例1-3使用的培养基,进行丁二磺酸腺苷蛋氨酸的制备,首先需要使用发酵培养基制备得到腺苷蛋氨酸,因此腺苷蛋氨酸质量的好坏直接影响最终产物的性能,根据表1的记载可知,使用常规发酵培养基培养,腺苷蛋氨酸的产量比较低,从而影响了丁二磺酸腺苷蛋氨酸的纯度;实施例4-6中对发酵培养基的配方进行了调整,加入了质量比2-4:1-2:1-2的脯氨酸、延胡索酸和Na2HPO4·12H2O能够明显腺苷蛋氨酸的产品收率,明显提高了终产物丁二磺酸腺苷蛋氨酸的纯度;当脯氨酸、延胡索酸和Na2HPO4·12H2O的添加量之比为4:2:1时,腺苷蛋氨酸的产品收率最高为3.9g/L,终产物丁二磺酸腺苷蛋氨酸的纯度99.95%;对比例1和对比例2改变脯氨酸、延胡索酸和Na2HPO4·12H2O的质量比不在本发明保护范围内时,,对比例3和对比例4省略脯氨酸和延胡索酸,降低了腺苷蛋氨酸的产品收率,使终产物丁二磺酸腺苷蛋氨酸的纯度也出现了一定程度的降低。
本发明并不局限于前述的具体实施方式。本发明扩展到任何在本说明书中披露的新特征或任何新的组合,以及披露的任一新的方法或过程的步骤或任何新的组合。
Claims (7)
1.一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法,其特征在于:包括以下步骤:
(1)将腺苷蛋氨酸产生菌接入活化培养基中,培养温度为24-32℃,培养3-5天,得到活化菌株;
(2)将步骤(1)中得到的活化菌株接种于一级种子培养基中,培养温度为24-32℃,培养12-25小时,得到一级种子;再将一级种子接种于下一级种子培养基中,培养温度为24-32℃,培养12-25小时,得到二级种子;
(3)将步骤(2)中得到的二级种子接入发酵培养基中,培养温度为24-32℃,发酵过程中pH为4.6-5.2,发酵过程中向发酵液中添加三磷酸腺苷和L-蛋氨酸,发酵40-50小时,得到腺苷蛋氨酸发酵液;
(4)将步骤(3)中得到的腺苷蛋氨酸发酵液进行破壁后过滤,纯化,浓缩,得到腺苷蛋氨酸浓缩液;
(5)向步骤(4)得到的腺苷蛋氨酸浓缩液中加入丁二磺酸然后进行冷冻干燥,即得到丁二磺酸腺苷蛋氨酸产品;
步骤(3)中所述的发酵培养基配方为葡萄糖5-8%、蛋白胨1-2%、酵母粉0.5-1.5%、K2HPO4 0.2-0.4%、KCl2 0.02-0.04%,脯氨酸0.4-0.8%、延胡索酸0.1-0.2%和Na2HPO4·12H2O 0.1-0.2%,pH为4.6-5.2;
所述的脯氨酸、延胡索酸和Na2HPO4·12H2O的添加量之比为2-4:1-2:1-2。
2.根据权利要求1所述的制备方法,其特征在于:步骤(1)中所述的活化培养基配方为葡萄糖2-5%、蛋白胨0.2-0.8%、酵母粉0.2-0.8%、琼脂1.2-2.5%;
步骤(2)中所述的一级种子培养基和二级种子培养基配方为葡萄糖2-5%、维生素B20.2-0.5%、蛋白胨0.2-0.8%、酵母粉0.2-0.8%。
3.根据权利要求1所述的制备方法,其特征在于:步骤(3)所述的脯氨酸、延胡索酸和Na2HPO4·12H2O的添加量之比为4:2:1。
4.根据权利要求1所述的制备方法,其特征在于:步骤(3)中所述的延胡索酸的浓度为5-8mmol/L。
5.根据权利要求1所述的制备方法,其特征在于:步骤(3)中所述的三磷酸腺苷的加入量为发酵培养基的0.4-0.8%。
6.根据权利要求5所述的制备方法,其特征在于:步骤(3)中所述的三磷酸腺苷的加入量为发酵培养基的0.6%。
7.根据权利要求1所述的制备方法,其特征在于:步骤(5)中所述的腺苷蛋氨酸和丁二磺酸的质量比为1:0.8-1.0。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011150316.0A CN112375797B (zh) | 2020-10-23 | 2020-10-23 | 一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011150316.0A CN112375797B (zh) | 2020-10-23 | 2020-10-23 | 一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112375797A CN112375797A (zh) | 2021-02-19 |
CN112375797B true CN112375797B (zh) | 2022-05-24 |
Family
ID=74575941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011150316.0A Active CN112375797B (zh) | 2020-10-23 | 2020-10-23 | 一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112375797B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113444757A (zh) * | 2021-06-23 | 2021-09-28 | 贵州卡本嘉泰生物科技产业发展有限公司 | 一种1,4-丁二磺酸腺苷蛋氨酸的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1191513A (en) * | 1966-11-17 | 1970-05-13 | Kyowa Hakko Kogyo Kk | Process for Producing Adenosine Triphoshate and Adenosine Diphosphate. |
CN102747123B (zh) * | 2012-07-31 | 2014-08-06 | 无锡福祈制药有限公司 | 丁二磺酸腺苷蛋氨酸的制备方法 |
CN104131052A (zh) * | 2014-08-06 | 2014-11-05 | 西藏金稞集团有限责任公司 | 一种利用酵母菌发酵生产腺苷蛋氨酸的方法 |
CN104878059B (zh) * | 2015-03-31 | 2018-06-26 | 浙江大学宁波理工学院 | 一种制备s-腺苷蛋氨酸的方法 |
-
2020
- 2020-10-23 CN CN202011150316.0A patent/CN112375797B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN112375797A (zh) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2402453B1 (en) | Method for increasing methionine productivity using a mixture of methyl mercaptan and dimethyl sulfide | |
JPS6192592A (ja) | 分岐サイクロデキストリンの製造方法 | |
CN109609580B (zh) | 一种核黄素的发酵培养基及其发酵方法 | |
CN112375797B (zh) | 一种用于保健功能的丁二磺酸腺苷蛋氨酸的制备方法 | |
WO2011110056A1 (zh) | 一种微生物生产环腺苷酸的方法 | |
CN113402570A (zh) | 一种烟酰胺单核苷酸的结晶方法 | |
CN1944661A (zh) | 胞磷胆碱钠的制备方法 | |
CN109371079A (zh) | 一种尿苷二磷酸葡萄糖及尿苷二磷酸葡萄糖醛酸的生物合成方法 | |
CN116426584A (zh) | 一种提高四氢嘧啶发酵产量的方法 | |
CN114134056A (zh) | 酿酒酵母zjs10041及其在发酵产s-腺苷蛋氨酸中的应用 | |
JP7213603B2 (ja) | ニコチンアミドを原料としてニコチンアミドモノヌクレオチドを調製する方法 | |
CN111218486B (zh) | 一种利用生物法合成乳糖酸的工艺 | |
CN104878059A (zh) | 一种制备s-腺苷蛋氨酸的方法 | |
TW200811287A (en) | A process for preparing dry yeast containing S-adenosyl-L-methionine and an oral composition | |
CN114164190B (zh) | 一种生产烟酰胺单核苷酸的融合酶及其应用 | |
CN112430636B (zh) | 一种生物法制造腺苷蛋氨酸的方法 | |
RU2711353C1 (ru) | Способ получения l-метионина | |
CN104178540B (zh) | 一种生物催化法合成腺苷蛋氨酸的方法 | |
CN104928342A (zh) | 一种制备s-腺苷蛋氨酸和d-蛋氨酸的方法 | |
CN112341508B (zh) | 一种腺苷蛋氨酸的分离纯化方法 | |
CN112142648A (zh) | 一种米格列醇的制备方法 | |
CN112941125A (zh) | 一种依利格鲁司特中间体的酶催化合成方法 | |
CN117025697B (zh) | 一种羟基树脂固定酶法生产腺苷蛋氨酸的方法 | |
CN109836464B (zh) | 一种果糖二磷酸钙的制备方法 | |
CN107259569A (zh) | 一种以蔗糖为原料制备新型功能性交替糖的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of adenosine methionine succinate for health functions Granted publication date: 20220524 Pledgee: Mongolian Commercial Bank Co.,Ltd. Hohhot Dazhao Branch Pledgor: INNER MONGOLIA BIOK BIOLOGY Co.,Ltd. Registration number: Y2024150000072 |